Results 41 to 50 of about 5,491,440 (299)

Rare-Earth Oxide Nanoparticles: A New Weapon Against Multidrug-Resistant Pathogens with Potential Wound Healing Treatment

Nanomaterials
Rare-earth oxide (REO) nanoparticles (NPs)—such as cerium (CeO2), samarium (Sm2O3), neodymium (Nd2O3), terbium (Tb4O7), and praseodymium (Pr2O3)—have demonstrated strong antimicrobial activity against multidrug-resistant bacteria.
Albert Donald Luong, Moorthy Maruthapandi, Aharon Gedanken, John H. T. Luong   +3 more
doaj   +1 more source

Mechanism-Based Inhibition of l-Pipecolate Oxidase by 4,5-Dehydro-l-Pipecolic Acid

, 2016
Mechanism-Based Inhibition of l-Pipecolate Oxidase by 4,5-Dehydro-l-Pipecolic ...
T. Mark Zabriskie (1476220)
core   +1 more source

Extraction Process of Mycosporine-like Amino Acids from Sargassum sp. and Its Inhibition Mechanism on the Activity of Tyrosinase

Shipin gongye ke-ji
To explore the effect of mycosporine-like amino acids (MAAs) extracted from Sargassum sp. on the activity of tyrosinase, this study first employed single-factor and response surface optimization experiments to analyze the effects of several factors such ...
Tianle LI, Xiujing JIANG, Mingxuan PAN, Xin WEI, Xue JIAO, Xinran WANG, Yadong HU, Yingying SUN   +7 more
doaj   +1 more source

Natural and Bioinspired Phenolic Compounds as Tyrosinase Inhibitors for the Treatment of Skin Hyperpigmentation: Recent Advances

Cosmetics, 2019
One of the most common approaches for control of skin pigmentation involves the inhibition of tyrosinase, a copper-containing enzyme which catalyzes the key steps of melanogenesis.
Lucia Panzella, Alessandra Napolitano
doaj   +1 more source

Correction: Menaquinone biosynthesis inhibition: a review of advancements toward a new antibiotic mechanism

, 2018
Correction for ‘Menaquinone biosynthesis inhibition: a review of advancements toward a new antibiotic mechanism’ by M. Boersch et al., RSC Adv., 2018, 8, 5099–5105.
Boersch, M, Grant, G, S. Rudrawar, Zunk, M, G. Grant, Rudrawar, S., M. Zunk, Rudrawar, S, M. Boersch, Boersch, M., Zunk, M., Grant, G.   +11 more
core   +1 more source

Performance and Mechanism of Alkylimidazolium Ionic Liquids as Corrosion Inhibitors for Copper in Sulfuric Acid Solution

Molecules, 2021
The addition of corrosion inhibitors is an economic and environmental protection method to prevent the corrosion of copper. The adsorption, performance, and mechanism of three 1-alkyl-3-methylimidazolium hydrogen sulfate ([BMIM]HSO4, [HMIM]HSO4, and ...
Guocai Tian, Kaitao Yuan
doaj   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin, Sheila K. Pierson, Kelley C. Dacus, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Larissa Borys, Kayla McHugh, Abiola Irvine, Yoojin Jo, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Amy Chadburn, Megan S. Lim, Gordan Srkalovic, Frits van Rhee, David C. Fajgenbaum, Joshua D. Brandstadter   +17 more
wiley   +1 more source

Exercise Capacity, Physical Activity, Fatigue, and Neurocognitive Function in Adult Survivors of Childhood Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Adult survivors of childhood acute lymphoblastic leukemia (ALL) are at risk of reduced exercise capacity, decreased physical activity levels, persistent fatigue, and neurocognitive deficits. The aim was to investigate exercise capacity and physical activity levels of adult survivors of childhood ALL and their associations with ...
Laura Jess, Gustaf Glavå, Simon Skau, Hans‐Georg Kuhn, Maria Bäck, Marianne Jarfelt   +5 more
wiley   +1 more source

Studies on the inhibitory effect of isavuconazole on flumatinib metabolism in vitro and in vivo

Frontiers in Pharmacology, 2023
As the validated agent for the treatment of chronic myelogenous leukemia (CML), flumatinib is a novel oral tyrosine kinase inhibitor (TKI) with higher potency and selectivity for BCR-ABL1 kinase compared to imatinib.
Ya-nan Liu, Ya-nan Liu, Xinhao Xu, Xinhao Xu, Jingjing Nie, Jingjing Nie, Yingying Hu, Xuegu Xu, Ren-ai Xu, Xiaoxiang Du   +9 more
doaj   +1 more source

Classical Complement Pathway Inhibition in a Pediatric Patient With Refractory Immune Thrombocytopenia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric refractory immune thrombocytopenia (rITP) is generally characterized by persistent thrombocytopenia and failure to achieve a sustained response to multiple standard therapies. We report a 4‐year‐old female with congenital tufting enteropathy, post‐intestinal transplant patient on immunosuppressants, who developed severe rITP ...
Sarah Hsieh, Susmita Sarangi, Caileigh Pudela, Catherine M. Broome, Tara K. Suntum   +4 more
wiley   +1 more source